| Dr Ranjan V Kumar, MD | |
|
600 Roe Ave, Elmira, NY 14905-1629 | |
| (607) 737-7770 | |
| (607) 271-3686 |
| Full Name | Dr Ranjan V Kumar |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 41 Years |
| Location | 600 Roe Ave, Elmira, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659667772 | NPI | - | NPPES |
| 03397257 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 262508 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Garnet Health Medical Center | Middletown, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crystal Run Healthcare Physicians Llp | 6901792696 | 395 |
News Archive
The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.
Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.
A radically different approach to treating high blood pressure - using a minimally invasive procedure- is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.
With research and development assistance from the Georgia Tech Research Institute (GTRI) and seed funding from the Georgia Research Alliance (GRA), an Atlanta-based company is developing what it hopes will be the next-generation instrument for optimizing eyesight for the hundreds of millions of people who wear glasses or contacts - or who are candidates for corrective surgery.
› Verified 3 days ago
| Entity Name | Crystal Run Healthcare Physicians Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952376410 PECOS PAC ID: 6901792696 Enrollment ID: O20040227000791 |
News Archive
The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.
Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.
A radically different approach to treating high blood pressure - using a minimally invasive procedure- is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.
With research and development assistance from the Georgia Tech Research Institute (GTRI) and seed funding from the Georgia Research Alliance (GRA), an Atlanta-based company is developing what it hopes will be the next-generation instrument for optimizing eyesight for the hundreds of millions of people who wear glasses or contacts - or who are candidates for corrective surgery.
› Verified 3 days ago
| Entity Name | Arnot Medical Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427326768 PECOS PAC ID: 0840450748 Enrollment ID: O20120330000383 |
News Archive
The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.
Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.
A radically different approach to treating high blood pressure - using a minimally invasive procedure- is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.
With research and development assistance from the Georgia Tech Research Institute (GTRI) and seed funding from the Georgia Research Alliance (GRA), an Atlanta-based company is developing what it hopes will be the next-generation instrument for optimizing eyesight for the hundreds of millions of people who wear glasses or contacts - or who are candidates for corrective surgery.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ranjan V Kumar, MD 571 Saint Josephs Blvd, Fl 2, Elmira, NY 14901-3230 Ph: (607) 271-2050 | Dr Ranjan V Kumar, MD 600 Roe Ave, Elmira, NY 14905-1629 Ph: (607) 737-7770 |
News Archive
The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.
Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.
A radically different approach to treating high blood pressure - using a minimally invasive procedure- is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.
With research and development assistance from the Georgia Tech Research Institute (GTRI) and seed funding from the Georgia Research Alliance (GRA), an Atlanta-based company is developing what it hopes will be the next-generation instrument for optimizing eyesight for the hundreds of millions of people who wear glasses or contacts - or who are candidates for corrective surgery.
› Verified 3 days ago
Emmanuel Oponde Misodi, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-737-7770 Fax: 607-271-3686 | |
Miss Janet M Maltez, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 602 Ivy St, Elmira, NY 14905 Phone: 607-735-4633 Fax: 607-735-4628 | |
Dr. Manav Bandlamudi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 Ivy St, Elmira, NY 14905 Phone: 607-737-8157 | |
Dr. Charles Junior Badger Ii, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-737-7770 Fax: 607-271-3686 | |
Dr. William George Newman, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-737-7770 Fax: 607-271-3686 | |
Dr. Vidhya A Reddy, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-737-7771 Fax: 607-271-3686 |